DUBLIN--(BUSINESS WIRE)--The "Global Myocardial Infarction Treatment Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The Global Myocardial Infarction Treatment Market is poised to grow strong during the forecast period 2017 to 2027.
Some of the prominent trends that the market is witnessing include increasing incidence of cardiovascular diseases, huge growth of chronic diseases such as diabetes, hypertension and chronic kidney diseases, recent technological developments in myocardial infarction treatment, and growth opportunities/investment opportunities.
This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
The study presents detailed market analysis with inputs derived from industry professionals across the value chain. A special focus has been made on 23 countries such as U.S., Canada, Mexico, U.K., Germany, Spain, France, Italy, China, Brazil, Saudi Arabia, South Africa, etc.
The market data is gathered from extensive primary interviews and secondary research. The market size is calculated based on the revenue generated through sales from all the given segments and sub segments in the research scope. The market sizing analysis includes both top-down and bottom-up approaches for data validation and accuracy measures.
- The report provides a detailed analysis on current and future market trends to identify the investment opportunities
- Market forecasts till 2027, using estimated market values as the base numbers
- Key market trends across the business segments, Regions and Countries
- Key developments and strategies observed in the market
- Market Dynamics such as Drivers, Restraints, Opportunities and other trends
- In-depth company profiles of key players and upcoming prominent players
- Growth prospects among the emerging nations through 2027
- Market opportunities and recommendations for new investments
Key Topics Covered
1 Market Outline
1.1 Research Methodology
1.1.1 Research Approach & Sources
1.2 Market Trends
1.3 Regulatory Factors
1.4 Product Analysis
1.5 Strategic Benchmarking
1.6 Opportunity Analysis
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Increasing Incidence of Cardiovascular Diseases
3.1.2 Huge Growth Chronic Diseases such as Diabetes, Hypertension and Chronic Kidney Diseases
3.1.3 Recent Technological Developments in Myocardial Infarction Treatment
3.1.4 Growth Opportunities/Investment Opportunities
3.4 Industry Attractiveness
3.4.1 Bargaining power of suppliers
3.4.2 Bargaining power of buyers
3.4.3 Threat of substitutes
3.4.4 Threat of new entrants
3.4.5 Competitive rivalry
4 Myocardial Infarction Treatment Market, By Product Type
4.1 Antithrombotic agents
4.2 Antiplatelet agents
4.3 Beta-adrenergic blockers
4.4 Angiotensin-Converting Enzyme (ACE) inhibitors
4.6.1 Morphine sulfate
4.7 Thrombolytics and anti-thrombotic agents
4.7.1 Alteplase (t-PA)
4.8 Angiotensin-Receptor blockers
4.9 Glycoprotein IIb/IIIa inhibitors
4.10 Plaque Modification Device
5 Myocardial Infarction Treatment Market, By Distribution Channel
5.1 Drug Stores
5.2 Hospital Pharmacies
5.3 Online Drug Stores
6 Myocardial Infarction Treatment Market, By Geography
6.1 North America
6.3 Asia Pacific
6.4 Middle East
6.5 Latin America
6.6 Rest of the World (RoW)
7 Key Player Activities
7.1 Acquisitions & Mergers
7.2 Agreements, Partnerships, Collaborations and Joint Ventures
7.3 Product Launch & Expansions
7.4 Other Activities
8 Leading Companies
8.1 Johnson & Johnson
8.3 Daiichi Sankyo Company Limited
8.4 Janssen Biotech, Inc.
8.5 Boehringer Ingelheim GmbH
8.6 Pfizer Inc.
8.9 Eli Lilly and Company
8.10 Bristol-Myers Squibb Company
8.11 Apotex Inc.
8.12 Par Pharmaceutical Companies, Inc.
8.13 Mylan N.V.
8.14 Portola Pharmaceuticals Inc.
8.15 GlaxoSmithKline PLC
8.16 Anthera Pharmaceuticals
8.17 Capricor Inc.
8.20 Merck & Co. Inc.
For more information about this report visit https://www.researchandmarkets.com/research/6jvfv4/global_myocardial?w=4